Clinical implementation of a new antibiotic prophylaxis regimen for percutaneous endoscopic gastrostomy

Lagergren, Jesper; Mattsson, Fredrik; Lagergren, Pernilla

http://doi.org/10.1136/bmjopen-2013-003067
http://hdl.handle.net/10616/41653

If not otherwise stated by the Publisher's Terms and conditions, the manuscript is deposited under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Clinical implementation of a new antibiotic prophylaxis regimen for percutaneous endoscopic gastrostomy

Jesper Lagergren,1,2 Fredrik Mattsson,1 Pernilla Lagergren1

ABSTRACT
Objectives: This study was undertaken to test the extent to which a new antibiotic prophylaxis regimen for percutaneous endoscopic gastrostomy (PEG), identified as a justified and simpler alternative to conventional regimen in a randomised clinical trial, has been adopted in clinical practice.

Design: A Swedish nationwide implementation survey, conducted in February 2013, assessed the level of implementation of a 20 ml dose of oral solution of sulfamethoxazole and trimethoprim deposited in the PEG catheter immediately after insertion. All hospitals inserting at least five PEGs annually were identified from the Swedish Patient Registry. A clinician involved in the PEG insertions at each hospital participated in a structured telephone interview addressing their routine use of antibiotic prophylaxis.

Setting: All Swedish hospitals inserting PEGs (n=60).

Participants: Representatives of PEG insertions at each of the 60 eligible hospitals participated (100% participation).

Main outcome measures: Use of routine antibiotic prophylaxis for PEG.

Results: A total of 32 (53%) of the 60 hospitals had adopted the new regimen. It was more frequently adopted in university hospitals (67%) than in community hospitals (41%). An annual total of 1813 (70%) of 2573 patients received the new regimen. Higher annual hospital volume was associated with a higher level of adoption of the new regimen (80% in the highest vs 31% in the lowest).

Conclusions: The clinical implementation of the new antibiotic prophylaxis regimen for PEG was high and rapid (70% of all patients within 3 years), particularly in large hospitals.

INTRODUCTION
A main goal of clinical research is to improve clinical practice. Yet, evaluations of the implementation of novel research findings are rare and the methodological quality of the existing literature is limited.1 The process from revealing a clinically relevant research finding to having it adopted in the clinical setting is often difficult and requires resources and directed implementation strategies.2–4 Many patients do not receive appropriate care or receive unnecessary or harmful treatments.5 This study was undertaken to evaluate the potential clinical implementation of a new antibiotic prophylaxis regimen used to reduce infectious complications after the insertion of percutaneous endoscopic gastrostomy (PEG) for enteral nutrition in patients with eating difficulties, as recommended in a randomised clinical trial published in 2010.6 The new regimen was a 20 ml dose of the oral solution of sulfamethoxazole and trimethoprim deposited in
Implementation of new antibiotic prophylaxis after PEG

the PEG catheter immediately after its insertion. This regimen was tested against a standard of an intravenous dose of 1.5 g cefuroxime administered 1 h before inserting PEG. The trial included 234 patients (116 with the new regimen and 118 with standard regimen), and all patients and evaluators were blinded to which prophylaxis was used. The study outcome was clinical signs of infection, supported by bacterial cultures and blood tests. The trial was a non-inferiority study, that is, if the new regimen was at least as effective as standard treatment it would be preferable since it had advantages that favoured its use, that is, easier to administer, cheaper, not given unnecessarily to the 10% of the cases where PEG is not possible to insert.\(^7\)\(^8\) The trial showed that the new regimen was at least as effective in preventing infections, and the results were published as an original article in BMJ.\(^6\) We hypothesised that the trial had changed clinical practice and tested this hypothesis in a nationwide Swedish survey.

METHODS

Presentation of the trial results

The trial that was assessed in this study was published in BMJ in 2010.\(^6\) Moreover, a summary of the study was published in the Swedish Medical Journal (Lakartidningen). An oral presentation of the trial was conducted at a National Swedish conference in surgery. Finally, the study was presented at a Swedish meeting for clinicians with an interest in PEG.

Study design and setting

This was a population-based, nationwide Swedish implementation survey. All hospitals that had conducted an average of at least five PEG insertions/year during the 3-year period 2009–2011 were identified from the Swedish Patient Registry. This registry is complete nationwide and collects data of all diagnoses and surgical procedures (including endoscopic procedures) during in-hospitalisations or specialist outpatient care, and has been found to have excellent completeness and accurateness.\(^9\) A project nurse contacted the clinician responsible for the PEG activities at each of the identified hospitals and conducted a structured telephone interview strictly according to a study questionnaire. There was no mention about the trial under study until after the questions about current antibiotic prophylaxis were completed. All interviews were completed during the period from 30 January to 28 February 2013. The fact that the test regimen was entirely new facilitated the assessment of its potential implication in the clinical setting. The study was approved by the Regional Ethical Review Board in Stockholm, Sweden.

Statistical analyses

The hospitals were categorised into three groups: (1) university hospitals, (2) county hospitals or (3) community hospitals. We also estimated the number of inserted PEGs for 2012. This was performed by calculating the arithmetic mean of the number of inserted PEGs during the 3-year period 2009–2011 according to the Swedish Patient Registry for each hospital, and then summarised for all patients. Furthermore, we stratified all patients in 2012 by the use of antibiotic regimen, and in a similar way stratified each category of hospital. An additional categorisation of the hospitals into quintiles, based on the ranking of each hospital according to the estimated mean number of patients, was also conducted. The data management and the diagrams were conducted using the SAS (V.9.2; SAS Institute Inc, Cary, North Carolina, USA).

RESULTS

There were 60 eligible hospitals in Sweden that inserted at least 5 PEGs/year. All these hospitals participated in the interviews (100% participation rate). A total of 17 (28%) hospitals did not routinely use any antibiotic prophylaxis, most being community hospitals (71%). The rates of implementation of the new regimen at all hospitals and at the three categories of hospitals are presented in table 1. The total number of hospitals which had implemented the new regimen was 32 (53%); among hospitals using antibiotic prophylaxis, this rate was 32 out of 43 (74%). The new regimen was most frequently adopted in university hospitals (67%), while it was less commonly adopted in community hospitals (41%). Of all hospitals that had introduced the new regimen, 25 (78%) had adopted the new regimen within the year 2011. Reasons for having changed to the new regimen are presented in table 1. The most common reason was having read the article published in BMJ (63%).

Translated to the number of patients, an annual total of 1813 (70%) of 2573 patients received the new regimen (figure 1, table 2). Excluding hospitals not using antibiotic prophylaxis, the frequency using the new regimen was 79%. A higher annual hospital volume was associated with an increased adoption of the new regimen; the frequency of use of the new regimen was 31% in the lowest quintile of hospitals and 80% in the highest (table 2). The distribution of antibiotic prophylaxis according to the number of patients treated at the three categories of hospitals showed a higher frequency of the new regimen in university hospitals (84%), followed by county hospitals (71%) and community hospitals (45%; figure 2).

DISCUSSION

This study shows that the new antibiotic prophylaxis, with a solution of sulfamethoxazole and trimethoprim given directly in the newly inserted PEG, had replaced standard prophylaxis with intravenously given antibiotics to a considerable extent in Sweden.

Methodological strengths of the study include the ability to identify all hospitals inserting PEGs in Sweden.
through the Patient Registry, making it population-based in design and reducing the risk of selection bias. The 100% complete inclusion of all eligible hospitals further counteracted biased selection. Finally, the use of structured telephone interviews to collect the data should minimise the misclassification of the information collected. These advantages should provide high internal validity of the study.\(^1\) The external validity, however, is uncertain since it is unknown whether the results in Sweden are representative of those of other countries. The trial being followed up was conducted in Sweden, which should facilitate its implementation in this country in particular, while the implementation in other countries might be more limited.

Scientific evidence suggests that enabling research findings to change clinical practice requires comprehensive approaches and effective strategies at different levels, tailored to specific settings and target groups.\(^3\)–\(^5\)

The present study shows that it is possible to influence clinical practice based on a single randomised clinical trial if the results are convincing and easy to adopt in routine care. The implementation of the new regimen tested in the present study was facilitated by the fact that it had practical advantages and was cheaper to use compared with the standard regimen. In other trials, the tested treatment might often be more complex to use and more costly, which might make its introduction into routine clinical use less likely. For example, another implementation study of an endoscopic procedure was a large cohort study in the USA which showed that low rates of duodenal biopsy remained in more recent calendar periods in patients with clinical indications for biopsy to identify coeliac disease despite clinical recommendations to conduct such biopsies more frequently.\(^10\)

University hospitals and PEG high-volume hospitals were clearly more likely to adopt the new regimen compared with smaller hospitals. This might be due to a higher academic interest and a higher interest in the PEG procedure, respectively, which might increase the

---

**Table 1** Use of antibiotic regimen as part of the insertion of percutaneous endoscopic gastrostomy in Sweden, presented as number of hospitals and hospitals divided by the three hospital categories community hospitals, county hospitals and university hospitals

<table>
<thead>
<tr>
<th></th>
<th>All hospitals (n=60)</th>
<th>Hospital category</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Per cent</td>
</tr>
<tr>
<td><strong>Antibiotic prophylaxis regimen</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New*</td>
<td>32</td>
<td>53</td>
</tr>
<tr>
<td>Other†</td>
<td>11</td>
<td>18</td>
</tr>
<tr>
<td>None</td>
<td>17</td>
<td>28</td>
</tr>
<tr>
<td><strong>Knowledge of the trial</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>38</td>
<td>63</td>
</tr>
<tr>
<td>No</td>
<td>22</td>
<td>37</td>
</tr>
<tr>
<td><strong>Hospitals using the new regimen</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Year of introduction</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>10</td>
<td>31</td>
</tr>
<tr>
<td>2011</td>
<td>15</td>
<td>47</td>
</tr>
<tr>
<td>2012</td>
<td>7</td>
<td>22</td>
</tr>
<tr>
<td><strong>Reason for introduction</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Read the article</td>
<td>20</td>
<td>63</td>
</tr>
<tr>
<td>Scientific meeting</td>
<td>7</td>
<td>22</td>
</tr>
<tr>
<td>Colleague</td>
<td>4</td>
<td>13</td>
</tr>
<tr>
<td>Unknown</td>
<td>1</td>
<td>3</td>
</tr>
</tbody>
</table>

*20 ml dose of oral solution of sulfamethoxazole and trimethoprim deposited in the PEG catheter immediately after insertion.
†Intravenously administered antibiotics before percutaneous endoscopic gastrostomy insertion.

**Figure 1** Use of antibiotic regimen as part of the insertion of percutaneous endoscopic gastrostomy in Sweden, presented as number of patients. New regimen: 20 ml dose of oral solution of sulfamethoxazole and trimethoprim deposited in the percutaneous endoscopic gastrostomy (PEG) catheter immediately after insertion. Other regimen: intravenously administered antibiotics before PEG insertion.
likelihood of reading scientific articles and willingness to adopt new treatments. The lack of use of any antibiotic prophylaxis was not negligible, which might not be entirely justified considering the amount of evidence showing a high risk of infectious complications, and an absolute risk reduction of such complications by 14–17% with the use of antibiotic prophylaxis.

Although it is pleasing to find such rapid and positive uptake of an innovation, any recommendation for uptake of this new practice should be made with caution since it is based on one clinical trial of 200 patients only. A systematic review, which incorporates multiple sources of evidence, might provide a stronger basis for changing clinical practice.

In conclusion, this nationwide complete Swedish survey provides encouraging evidence of a high (55% of all hospitals and 70% of all patients) and rapid clinical implementation of a new antibiotic prophylaxis regimen for PEG based on the results of one well-designed randomised clinical trial. The level of adoption of the new regimen was substantially higher in university hospitals and PEG high-volume hospitals compared with smaller hospitals. This should encourage further randomised clinical trials addressing clinically relevant topics.

Acknowledgements We are grateful to the research nurse Isabella Linder Rosén for conducting all interviews.

Contributors JL had the original idea to conduct this study. JL and PL planned the study and completed the data collection. FM did the analyses, tables and figures. JL made the first draft of the article, and PL and FM contributed with input on the article writing. JL is responsible for the overall content as guarantor. All authors have read and approved the final manuscript.

Funding The Swedish Research Council (SIMSAM) and through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet.

Competing interests None.

Ethics approval The study was approved by the Regional Ethical Review Board in Stockholm, Sweden (diary number 2013/131-32).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data sharing: full dataset and statistical code are available from the corresponding author at jesper.lagergren@ki.se.

STROBE guidelines We followed the recommendation of the STROBE guidelines for observational studies.

REFERENCES


Clinical implementation of a new antibiotic prophylaxis regimen for percutaneous endoscopic gastrostomy

Jesper Lagergren, Fredrik Mattsson and Pernilla Lagergren

BMJ Open 2013 3:
doi: 10.1136/bmjopen-2013-003067

Updated information and services can be found at:
http://bmjopen.bmj.com/content/3/5/e003067.full.html

These include:

Data Supplement
"Supplementary Data"
http://bmjopen.bmj.com/content/suppl/2013/05/24/bmjopen-2013-003067.DC1.html

References
This article cites 10 articles, 2 of which can be accessed free at:
http://bmjopen.bmj.com/content/3/5/e003067.full.html#ref-list-1

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See:
http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Evidence based practice (117 articles)
Gastroenterology and hepatology (47 articles)
Health services research (254 articles)
Medical management (43 articles)
Nutrition and metabolism (70 articles)
Pharmacology and therapeutics (153 articles)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/